Your browser doesn't support javascript.
loading
Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol.
Weller, Amber; Gleeson, John; Alvarez-Jimenez, Mario; McGorry, Patrick; Nelson, Barnaby; Allott, Kelly; Bendall, Sarah; Bartholomeusz, Cali; Koval, Peter; Harrigan, Susy; O'Donoghue, Brian; Fornito, Alex; Pantelis, Christos; Paul Amminger, G; Ratheesh, Aswin; Polari, Andrea; Wood, Stephen J; van der El, Kristi; Ellinghaus, Carli; Gates, Jesse; O'Connell, Jessica; Mueller, Marianne; Wunderink, Lex; Killackey, Eóin.
Afiliação
  • Weller A; Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
  • Gleeson J; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Alvarez-Jimenez M; Australian Catholic University, Melbourne, Victoria, Australia.
  • McGorry P; Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
  • Nelson B; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Allott K; Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
  • Bendall S; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Bartholomeusz C; Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
  • Koval P; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Harrigan S; Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
  • O'Donoghue B; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Fornito A; Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
  • Pantelis C; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Paul Amminger G; Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
  • Ratheesh A; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Polari A; School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia.
  • Wood SJ; Centre for Mental Health, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
  • van der El K; Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
  • Ellinghaus C; Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Gates J; Melbourne Health, Melbourne, Victoria, Australia.
  • O'Connell J; Monash Clinical and Imaging Neuroscience, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.
  • Mueller M; Melbourne Neuropsychiatry Centre, Melbourne, Victoria, Australia.
  • Wunderink L; Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
  • Killackey E; Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Victoria, Australia.
Early Interv Psychiatry ; 13(6): 1345-1356, 2019 12.
Article em En | MEDLINE | ID: mdl-30488637

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Antipsicóticos / Uso Off-Label Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Antipsicóticos / Uso Off-Label Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article